UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Chordoma
The purpose of this Phase I clinical trial is to evaluate the safety and dosage of tazemetostat in treating children and young adults with relapsed or refractory tumors, including AT/RT and chordoma.
Conditions
Glioma
Glioblastoma (grade IV)
This phase I/II study is intended to explore a new potentially active mechanism of action that is cancer-specific in GBM patients who have exhausted standard of care that impacts survival.
Conditions
Glioma
Glioblastoma (grade IV)
The purpose of this Phase I/IIa clinical trial is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of FORE8394 in participants with advanced solid tumors, advanced, unresectable solid tumors with activating BRAF mutations, or primary central nervous system (CNS) tumors harboring BRAF mutations.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioblastoma (grade IV)
Glioma
This phase II study will evaluate the safety and efficacy of berubicin for people with recurrent glioblastoma multiforme. Berubicin is a novel anthracycline-based topoisomerase II inhibitor that crosses the blood-brain barrier and overcomes drug resistance.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with advanced, relapsed, or refractory malignant solid tumor or lymphoma.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Conditions
Glioma
Meningioma
Astrocytoma
Oligodendroglioma
The goal of this prospective cross-sectional study is to establish the content validity of the available patient-reported outcome (PRO) measures used in primary and secondary brain tumor patients.